Childhood Visual Pathway Glioma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Visual pathway gliomas (VPGs), also called optic pathway gliomas, are low-grade astrocytomas — typically WHO grade 1 pilocytic astrocytomas — arising in the optic nerves, optic chiasm, optic tracts, optic radiations, or hypothalamus. They account for approximately 5% of all pediatric CNS tumors and are the most common brain tumor affecting the optic pathway. They occur predominantly in children under age 10, with peak incidence between ages 2 and 6. Two clinically distinct populations exist: those with neurofibromatosis type 1 (NF1), who account for 30-50% of all cases and tend to have more indolent tumors often detected incidentally on surveillance MRI; and sporadic cases without NF1, which more commonly involve the optic chiasm and hypothalamus and carry greater risk of visual morbidity, endocrine dysfunction, and tumor progression. Management is individualized based on tumor location, NF1 status, rate of progression, and degree of visual impairment.

NF1 germline loss-of-function mutation (chromosome 17q11.2) is the most important risk factor, present in 30-50% of VPG patients; the NF1 protein (neurofibromin) is a RAS-GAP that normally suppresses RAS-MAPK signaling — its loss leads to constitutive MAPK activation. NF1 patients have a 15-20% lifetime probability of developing optic pathway glioma, and up to 50% of NF1-associated optic gliomas are asymptomatic throughout life. Sporadic VPGs most commonly harbor BRAF-KIAA1549 fusion (approximately 60-70% of sporadic chiasmatic/hypothalamic PA) arising from chromosome 7q34 tandem duplication, constitutively activating the MAPK pathway. BRAF V600E mutation characterizes a distinct sporadic subset with potentially more aggressive behavior and eligibility for BRAF-targeted therapy. No established environmental risk factors for VPG exist beyond NF1 inheritance.

Symptoms depend on tumor location. Optic nerve glioma (unilateral): progressive loss of visual acuity in the affected eye, proptosis (eye protrusion from orbital tumor expansion), and afferent pupillary defect (Marcus Gunn pupil). Chiasmatic glioma: bilateral visual acuity loss, bitemporal visual field defects (hemianopia), nystagmus (pendular or searching eye movements), and strabismus. Hypothalamic involvement causes the diencephalic syndrome in infants — a characteristic constellation of failure to thrive, profound emaciation despite normal or increased caloric intake, and paradoxically alert and euphoric behavior; precocious puberty from disruption of GnRH pulsatility; diabetes insipidus; growth hormone deficiency; and behavioral changes. Raised intracranial pressure from CSF obstruction causes headache, vomiting, and papilledema. NF1-associated tumors may be entirely asymptomatic and discovered only on scheduled surveillance MRI.

MRI brain and orbits with gadolinium contrast is the definitive imaging modality: T2 hyperintensity and variable enhancement characterize VPGs; chiasmatic gliomas typically show a massively enlarged, enhancing chiasm with or without hypothalamic extension. Ophthalmological assessment is mandatory: best-corrected visual acuity (preferably quantitative with ETDRS charts in cooperative children), visual field testing (Humphrey), fundoscopy (optic disc pallor indicates chronic atrophy), and visual evoked potentials (VEP) as an objective functional measure. NF1 genetic testing is offered to all patients — clinical diagnosis of NF1 may be possible from characteristic skin findings (café-au-lait macules ≥6, axillary freckling, Lisch nodules on slit-lamp examination). Biopsy is usually avoided for classic chiasmatic or hypothalamic tumors due to high surgical risk — molecular information is obtained from next-generation sequencing of CSF or tumor tissue when biopsy is performed for atypical presentations.

Asymptomatic NF1-associated optic pathway gliomas: surveillance with serial MRI (every 6-12 months) and ophthalmological assessment (every 6 months) without treatment — many remain stable for years. Treatment is initiated only when progressive visual loss, worsening MRI, or clinical deterioration occurs. First-line chemotherapy for progressive disease: carboplatin plus vincristine (COG A9952 protocol) for 70 weeks — response rate approximately 60% with disease stabilization. MEK inhibitors (selumetinib 25 mg/m2 BD orally) approved by FDA for NF1-associated symptomatic, inoperable plexiform neurofibromas; demonstrated significant radiological response (ORR 40%) for NF1-associated low-grade glioma in the FIREFLY-1 trial. BRAF V600E-positive tumors: dabrafenib plus trametinib. Second-line: carboplatin alone, temozolomide, or vinorelbine. Radiotherapy: deferred until age 5-7 at earliest due to neurocognitive, endocrine, and vascular toxicity risks in young children; reserved for refractory, progressive disease in older children. Surgery limited to diagnostic biopsy (atypical presentations) or debulking of anterior optic nerve gliomas causing severe unilateral proptosis in an already-blind eye.

Prognosis for visual pathway glioma is highly variable and reflects the heterogeneous clinical spectrum. NF1-associated optic pathway gliomas have generally favorable prognosis: approximately 50% never require treatment, and even among those that progress, 5-year OS exceeds 95% and 10-year OS exceeds 90% with appropriately sequenced treatment. Sporadic chiasmatic and hypothalamic gliomas without NF1 have a more guarded prognosis: 10-year OS approximately 80-90%, but visual morbidity and hypothalamic dysfunction cause significant long-term functional impairment. The primary threat from VPG is not death but irreversible visual loss and hypothalamic damage, occurring in approximately 20-30% of patients with chiasmatic or hypothalamic involvement regardless of tumor control. Visual acuity at diagnosis is the most important functional prognostic indicator; once vision is lost to optic atrophy, recovery is limited even with excellent radiological tumor control. MEK inhibitor therapy with selumetinib achieves objective tumor shrinkage in approximately 40% of NF1-associated tumors (FIREFLY-1 trial) and may improve or stabilize visual outcomes if commenced before severe optic atrophy develops. Radiation therapy, while effective for tumor control, carries late risks of neurocognitive impairment, endocrine dysfunction, and moyamoya vasculopathy in NF1 patients. Prognostic factors include NF1 status (favorable), tumor location (optic nerve versus chiasm or hypothalamus — chiasmatic involvement is less favorable for vision), degree of visual impairment at presentation, age at diagnosis, and rate of tumor progression. Long-term follow-up includes ophthalmological assessment and visual evoked potentials every 6-12 months, brain MRI annually, and endocrine evaluation for growth hormone deficiency, precocious puberty, and diabetes insipidus at each annual review.

Sporadic VPGs have no established preventive measures. For NF1-associated visual pathway gliomas, the primary prevention strategy is genetic counseling enabling family members to understand the 50% autosomal dominant inheritance risk of NF1. Confirmed NF1 diagnosis in children should trigger enrollment in an NF1 surveillance program: ophthalmological examination annually from diagnosis to age 8 (or more frequently if abnormalities detected), and brain MRI surveillance, particularly of the optic pathways, per national NF1 clinical management guidelines. Early detection of VPGs on surveillance enables treatment initiation before significant irreversible visual loss has occurred. Parents of children with NF1 should be taught to recognize warning signs of VPG — squinting, head tilting, bumping into objects, and declining school performance — and promptly report these to their specialist. Avoiding unnecessary cranial irradiation in NF1 patients reduces secondary tumor and moyamoya vasculopathy risk.

Seek prompt pediatric ophthalmological and neurological evaluation for any child who: fails a school vision screening test; develops a new squint or strabismus (eye misalignment); is observed to tilt or turn the head to compensate for impaired vision; bumps into objects or appears visually inattentive; develops proptosis (one eye appearing more prominent than the other); shows nystagmus (rhythmical involuntary eye movements); develops failure to thrive or unexplained weight loss in infancy; or presents with signs of raised intracranial pressure (headache, vomiting, papilledema). Children with NF1 must attend their scheduled ophthalmological surveillance appointments, particularly between ages 0 and 8 when VPG incidence peaks. Any NF1 child with an abnormal visual acuity measurement or asymmetric VEP requires urgent MRI brain and orbits to exclude VPG, even before symptoms are apparent.